English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine BioTech
Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting
Nov 13, 2017 15:00 HKT
Nanobiotix provides update on the global development of its lead product NBTXR3
Nov 10, 2017 08:30 HKT
Singapore eDevelopment's Biomedical Subsidiary Confirms 100% Repellency of 3F Mosquito Fragrance
Nov 01, 2017 18:00 HKT
SGX-Listed Singapore eDevelopment's Global BioLife Inc Develops Breakthrough Modified Sugar
Oct 24, 2017 18:00 HKT
Nanobiotix Completes Patient Inclusion for Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma
Oct 23, 2017 14:00 HKT
ASX-Listed Holista and Holista Foods Inc. (USA) Develop Breakthrough Noodle Formula with Low-Glycemic Score of 38
Oct 19, 2017 16:00 HKT
Helsinn Pharmaceuticals (Beijing) Co. Ltd. Opens Office in Shanghai, China
Oct 17, 2017 14:30 HKT
Sanofi: Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent(R) (alirocumab)
Oct 06, 2017 08:00 HKT
Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S.
Sep 29, 2017 08:00 HKT
Nanobiotix half year results for the six months ended 30 June 2017
Sep 01, 2017 01:30 HKT
Kingworld Medicines 1H2017 Profit Up10.1% to RMB22.1 Million; EPS Surges 20%
Aug 30, 2017 13:04 HKT
康臣药业收入规模增长超70% 坚定走向更高质量增长
Aug 25, 2017 15:26 HKT
康臣葯業收入規模增長超70% 堅定走向更高品質增長
Aug 25, 2017 15:23 HKT
上海医药与DHL达成战略合作,共同拓展中国医药物流市场
Aug 04, 2017 16:52 HKT
上海醫藥與DHL達成戰略合作,共同拓展中國醫藥物流市場
Aug 04, 2017 16:50 HKT
王振義院士談:期待治療MDS的中國新藥和中國研究
Jul 25, 2017 18:28 HKT
王振义院士谈:期待治疗MDS的中国新药和中国研究
Jul 25, 2017 18:30 HKT
马军教授:MDS——临床医生的挑战,创新药物的机遇
Jul 21, 2017 13:24 HKT
馬軍教授:MDS——臨床醫生的挑戰,創新藥物的機遇
Jul 21, 2017 13:22 HKT
联康生物科技获香江大健康基金注资1.2亿港元 成为集团策略性股东
Jul 19, 2017 08:27 HKT
Next >>
Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: